News – Droia Ventures – Investing in Impact

Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

“The continued support for Cyteir from highly knowledgeable investors reflects the growing excitement around our novel application of synthetic lethality,” said Markus Renschler, M.D., Cyteir president and CEO. “This financing will support the recently launched first-in-human phase 1/2 study of CYT-0851 while simultaneously allowing us...

15 October, 2019

PACT Pharma Appoints Tim Moore as President and Chief Technical Officer

Mr. Moore has over three decades of leadership experience in biopharmaceutical manufacturing and operations. He most recently served as Executive Vice President, Technical Operations of Kite, a Gilead Company since March of 2016. While at Kite, Mr. Moore oversaw the process development, manufacturing, quality and...

02 October, 2019

FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019

“This year has seen unrivalled scientific talent in the early-stage life sciences world. It has been a pleasure to for us at FierceBiotech to speak to all 15 winners and hear their passion, progress and panache,” said Ben Adams, Senior Editor of FierceBiotech. “Each company...

23 September, 2019

Accent Therapeutics appoints Shakti Narayan as chief executive officer

Dr. Narayan brings a strong record of experience in life sciences, having held various leadership roles which led to transformational achievements within both the biotechnology and pharmaceutical industries....

03 September, 2019

Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer

Dr Cautreels succeeds Simon Sturge, who steps down to focus on his new role as CEO at Kymab. In addition, Andre Verwei is appointed as Chief Financial Officer (CFO) with immediate effect....

01 August, 2019

Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies

“We are thrilled to welcome Kevin, Johannes and Jim to Frontier Medicines as we continue to build a best-in-the-business team to address previously inaccessible disease-causing proteins,” said Chris Varma, Ph.D., co-founder and CEO of Frontier Medicines. “Kevin, Johannes and Jim bring deep science, biopharma and...

31 July, 2019

Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the “Undruggable” Targets Driving Human Disease

“Our platform currently includes a database of hotspots that cover a majority of human proteins, including those that were previously considered ‘undruggable;’ an expanding library of diverse, covalent compounds being driven by machine learning; and a novel approach to protein degradation,” said Daniel K. Nomura,...

25 June, 2019

OCTIMET Oncology announces the appointment of Shelley Margetson as CEO

Shelley brings a skill set that very much complements and strengthens the existing management team in keeping with current stage of the company. We are grateful to Tim for bringing the company so far and are looking forward to the team progressing the company further”...

20 May, 2019

Aura Biosciences Completes $40 Million Series D Financing

The Company plans to use the proceeds from the Series D financing to support the late stage clinical development of their lead asset, light-activated AU-011, for the treatment of primary choroidal melanoma....

02 April, 2019

FDA Approves OCTIMET’s Investigational New Drug Application to evaluate OMO-1 in patients

This first-in-patient trial is primarily evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of the MET kinase inhibitor OMO-1 alone and in combination with anti-cancer treatments....

29 January, 2019